Prospective Validation of a 21-Gene Expression Assay in Breast Cancer (Q29011698)

23 March 2017

Soonmyung Paik

18

0 references

E Claire Dees

8

object named as

Elizabeth C. Dees

1 reference

23 March 2017

9

Edith A. Perez

1 reference

23 March 2017

31

George W. Sledge

1 reference

23 March 2017

1

Joseph A. Sparano

1 reference

23 March 2017

author name string

Robert J. Gray

2

1 reference

23 March 2017

Della F. Makower

3

1 reference

23 March 2017

Kathleen I. Pritchard

4

1 reference

23 March 2017

Kathy S. Albain

5

1 reference

23 March 2017

Daniel F. Hayes

6

1 reference

23 March 2017

Charles E. Geyer

7

1 reference

23 March 2017

John A. Olson

10

1 reference

23 March 2017

JoAnne Zujewski

11

1 reference

23 March 2017

Tracy Lively

12

1 reference

23 March 2017

Sunil S. Badve

13

1 reference

23 March 2017

Thomas J. Saphner

14

1 reference

23 March 2017

Lynne I. Wagner

15

1 reference

23 March 2017

Timothy J. Whelan

16

1 reference

23 March 2017

Matthew J. Ellis

17

1 reference

23 March 2017

William C. Wood

19

1 reference

23 March 2017

Peter Ravdin

20

1 reference

23 March 2017

Maccon M. Keane

21

1 reference

23 March 2017

Henry L. Gomez Moreno

22

1 reference

23 March 2017

Pavan S. Reddy

23

1 reference

23 March 2017

Timothy F. Goggins

24

1 reference

23 March 2017

Ingrid A. Mayer

25

1 reference

23 March 2017

Adam M. Brufsky

26

1 reference

23 March 2017

Deborah L. Toppmeyer

27

1 reference

23 March 2017

Virginia G. Kaklamani

28

1 reference

23 March 2017

James N. Atkins

29

1 reference

23 March 2017

Jeffrey L. Berenberg

30

1 reference

23 March 2017

language of work or name

English

0 references

publication date

19 November 2015

1 reference

The New England Journal of Medicine

23 March 2017

published in

1 reference

23 March 2017

volume

373

1 reference

23 March 2017

issue

21

1 reference

23 March 2017

page(s)

2005-2014

1 reference

Validation of new cancer biomarkers: a position statement from the European group on tumor markers

23 March 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Biomarker validation and testing

23 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

23 March 2017

Cancer statistics, 2014

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

23 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

The MINDACT trial: the first prospective clinical validation of a genomic tool

23 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

23 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

23 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Markers for the identification of late breast cancer recurrence

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Global patterns of cancer incidence and mortality rates and trends

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Clinical application of gene expression profiling in breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Use of archived specimens in evaluation of prognostic and predictive biomarkers

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Development of the 21-gene assay and its application in clinical practice and clinical trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Adjuvant therapy for breast cancer--results from the USA consensus conference

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4701034

Predictive and prognostic markers in cancer

26 November 2018

1 reference

12 December 2020

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

12 December 2020

Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study

1 reference

12 December 2020

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

12 December 2020

Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1510764

2 references

23 March 2017

253172

253172

1 reference

1 reference

1 reference